MarketBeat
17 Nov 2026, 01:17 UTC · 1h ago
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Impact · against what's priced in
Aquestive Therapeutics (AQST) gains a concrete valuation catalyst with a March 16, 2027, FDA decision date and a clear funding path for launch. The clinical differentiation of a 12-minute peak absorption versus 20 minutes for auto-injectors provides a tangible basis for the company's $2 billion market projection.
- AQST+0.60
No priced-in read yet





